INKA Entworks Announces $8.2 Million Investment to Drive Global Expansion and AI-Driven Product Innovation
21.1.2025 16:00:00 EET | Business Wire | Press release
INKA Entworks, a global leader in video content security and mobile app security solutions, has secured $8.2 million in a funding round led by SV Investment, with co-investments from DSC Investment, Stonebridge Ventures, Inopolis Partners, and IBK Industrial Bank. This investment reinforces INKA Entworks' position as a market leader and sets the stage for significant growth and innovation in 2025 and beyond.
The funding will enable INKA Entworks to expand its portfolio of cutting-edge video content security and robust mobile app security Saas solutions. The company aims to deliver advanced revenue-securing technologies to key markets, including media, sports, banking, fintech, and retail, while also driving product enhancements leveraging AI capabilities. Additionally, the funding will accelerate INKA Entworks' expansion into the U.S. and European markets and bolster its recruitment efforts to attract top talent.
Lee Sung-min, Team Leader of SV Investment’s VC Division, commented, “It is remarkable that a domestic software company has achieved phenomenal growth with 60% of revenue coming from overseas. This investment will support INKA Entworks in securing major North American and European clients and solidifying its leadership in the video content and app security markets with AI-driven solutions.”
INKA Entworks has achieved an impressive compound annual growth rate (CAGR) of 43% in overseas sales over the past three years, underscoring its ability to scale effectively. The company’s innovative SaaS solutions PallyCon and AppSealing have been instrumental in preventing hacking and illegal duplication, earning the trust of content operators and mobile app developers worldwide. Its clientele includes prominent names such as DAZN, Schneider Electric, PCCW, VIU, Vidio, LGU+, Bajajfinsev, and Prasar Bharti showcasing its broad industry reach.
“As the first domestic company to provide mobile app and content security technologies in a SaaS format, we have contributed to the growth of the security industry,” said James Sungmin Ahn, CEO of INKA Entworks. “This investment will solidify our position in South Korea and propel our efforts to succeed globally.”
The company’s immediate focus includes enhancing product innovation, expanding its global reach, and strengthening its leadership to set new benchmarks in digital security, paving the way for a secure digital future.
About INKA Entworks
INKA Entworks is a global leader in content security and mobile app security solutions, providing innovative technologies to protect digital assets across industries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250120715815/en/
Contacts
Media Contact:
Rupesh Shinde
obiz@inka.co.kr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OPEX® Corporation Introduces the Velo™ Series of Premium Desktop and High Production Document Scanners10.2.2026 11:00:00 EET | Press release
OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, has announced the launch of its Velo™ Series powered by InoTec, a new class of premium desktop and free standing high production scanners. The OPEX Velo scanners are engineered to deliver exceptional performance, reliability and image quality and offer industry-standard TWAIN/ISIS connectivity to help simplify deployment into existing capture environments. These state-of-the-art scanners are ideal for service bureaus, government agencies, healthcare providers and enterprise capture operations. “The Velo Series powered by InoTec introduces an entirely new class of scanners to the OPEX portfolio, expanding the options available to both our current customers and organizations considering OPEX for the first time,” said Dann Worrell, President, Document and Mail Automation, OPEX. “By broadening our offerings, we can better align the right solution with
New ZOLL Zenix Monitor/Defibrillator Receives MDR Approval10.2.2026 11:00:00 EET | Press release
ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that Zenix®, the company’s most clinically advanced and easy-to-use professional monitor/defibrillator, is approved under the European Union (EU) Medical Device Regulation 2017/745, commonly referred to as EU MDR. The Zenix monitor/defibrillator is a groundbreaking device that redefines efficiency, clarity, and intelligence in both EMS and hospital settings. Built from years of feedback from customers, Zenix combines intuitive design with powerful functionality to enhance patient care and automate workflows for ease-of-use. Featuring a large, durable touchscreen, Zenix provides critical information when it’s needed. With on-the-fly customization, healthcare professionals can make real-time adjustments, helping them stay in control during high-pressure situations. Equipped with ZOLL’s innovative Real BVM Help® and exclusive Real CPR Help® technology, Zenix gives healthcare pro
IEO and Laife Reply Join Forces to Digitalise the Biobank Through Artificial Intelligence10.2.2026 11:00:00 EET | Press release
The Pathology Division of the European Institute of Oncology (IEO) and Laife Reply, the Reply Group company specialised in AI and Big Data solutions for the healthcare sector, have entered into a collaboration to develop Bianca, the first project in Italy aimed at creating an AI-based digital biobank designed as an integral part of clinical diagnostic practice. The initiative is part of a broader technological innovation journey that structurally integrates research and development into routine diagnostic processes in pathology, transforming the traditional histopathological sample workflow into an end-to-end digital ecosystem. The complete digitalisation of histopathological and molecular diagnostic workflows aims to make analysis more efficient, scalable and reproducible, laying the foundations for the evolution of AI-supported oncological diagnostics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210610418/en/ On this
Expereo Elevates expereoOne with New Digital Case Management Capabilities, Delivering Faster, Clearer and More Predictable Service Resolution10.2.2026 11:00:00 EET | Press release
Expereo is redefining what’s possible for global enterprises at CiscoLive Amsterdam with the launch of its enhanced Digital Case Management (DCM) capability in expereoOne. As the world-leading managed Network as a Service (NaaS) provider, Expereo is putting customers firmly in control - slashing resolution times, cutting through operational noise and ensuring everyone is aligned every step of the way. With DCM, service issues are no longer bottlenecks: instead, enterprises experience swift, transparent outcomes, with every stakeholder empowered through a single, real-time view of progress. DCM is designed around a simple objective: enable enterprises to resolve issues faster, with greater clarity and full control, through a fully digital, software-first workflow inside expereoOne. Customers can create, manage and track cases end-to-end within a single platform, ensuring predictable, consistent and aligned service experiences across their global network footprint. Unified, digital-first
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 110.2.2026 10:15:00 EET | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the treatment of narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year. Takeda remains on track to potentially bring the first approved orexin agonist treatment to people living with NT1. NT1 is a chronic, rare neurological disease caused by a loss of orexin and characterized by excessive daytime sleepiness and cataplexy (sudden loss of muscle tone). This results in a spectrum of physical, cognitive and psychosocial effects that can have a debilitating impact on many aspects of a person’s life, including work, education and social interactio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom